Navigation Links
TetraLogic Pharmaceuticals Announces Presentation of Data on Smac Mimetic TL32711 at AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics
Date:11/13/2011

MALVERN, Pa., Nov. 13, 2011 /PRNewswire/ -- TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced presentations of new data on its Smac mimetic drug candidate TL32711 at the 2011 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics in San Francisco. TL32711 is nearing completion of a single agent Phase 1 study in solid tumors and lymphomas and a Phase 1b five-arm combination clinical study in solid tumors.

In a poster entitled "Phase 1 PK/PD Analysis of the Smac Mimetic TL32711 Demonstrates Potent and Sustained cIAP1 Suppression in Patient PBMC and Tumor Biopsies" (Abstract # A25), the degradation and suppression of cIAP1 was analyzed as part of the single agent Phase 1 study. The data demonstrated that TL32711 causes potent and sustained suppression of inhibitor of apoptosis protein cIAP1 in patient peripheral blood mononuclear cells (PBMCs) and tumor biopsies over 7 days at tolerable dose levels with evidence of apoptosis pathway activation and promising early signs of anti-tumor activity in patients.

In a poster entitled "Dose scheduling and efficacy analysis of the Smac mimetic TL32711 in primary melanoma tumor xenotransplant models" (Abstract # A225), tumor growth inhibition was observed in primary melanoma tumor xenografts following treatment with single agent TL32711.  Combining TL32711 with carboplatin and paclitaxel resulted in a further enhancement in anti-tumor efficacy with tumor regressions without any marked changes in tolerability.

About TL32711

TL32711 is a small molecule peptidomimetic of Smac (Second mitochondrial-derived activator of caspases) an endogenous regulator of apoptotic cell death that selectively antagonizes multiple IAPs. TL32711 has demonstrated preclinical anti-tumor activity that supports its clinical development for solid tumor and hematological malignancies as a monotherapy and in combination with other anti-cancer therapies. TL32711 is nearing completion of a single agent Phase 1 study in solid tumors and lymphomas and a Phase 1b five-arm combination clinical study in solid tumors. In the clinical studies to date, TL32711 has been well tolerated and exhibited target suppression and antitumor activity.

About TetraLogic Pharmaceuticals
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that focuses on the discovery and development of Smac mimetics, small molecule drugs that mimic Smac (Second mitochondrial-derived activator of caspases) for the treatment of cancers. The company's institutional investors include Clarus Ventures, HealthCare Ventures, Quaker BioVentures, Novitas Capital, Nextech Invest Ltd, Hatteras Venture Partners, Pfizer Ventures, Latterell Venture Partners, the Vertical Group, Amgen Ventures, and Kammerer Associates. For additional information, please refer to the company's Web site at www.tetralogicpharma.com.

Media Contact:

Russo Partners, LLC
Tony Russo, Ph.D., or Andreas Marathovouniotis
212-845-4251 or 212-845-5235
tony.russo@russopartnersllc.com
andreas.marathis@russopartnersllc.com

TetraLogic Pharmaceuticals
James Goldschmidt, Ph.D.
610-889-9900


'/>"/>
SOURCE TetraLogic Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TetraLogic Closes $23 Million Second Tranche of Series C Financing
2. TetraLogic Closes $6 Million Series C-1 Investment with Nextech Invest Ltd.
3. TetraLogic Appoints Jonathan B. Lloyd Jones as Chief Financial Officer and Vice President Corporate Development
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ALBANY, New York , May 26, 2016 ... Transparency Market Research "Medical Waste Management Market - U.S. Industry ... the medical waste management market in the U.S. was valued ... expand at a CAGR of 3.4% from 2015 to 2023 ... report provides exhaustive analysis of current and emerging needle free ...
(Date:5/26/2016)... May 26, 2016   Change Healthcare ... analytics, network solutions and technology-enabled services designed ... entered into a strategic channel partnership with ... software solutions and revenue cycle management services ... and rehabilitation clinics to optimize revenue, operational ...
(Date:5/25/2016)... -- According to a new market research ... by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by Application (Drug ... Hospitals/ Clinics) - Forecast to 2021", published by MarketsandMarkets, ... the forecast period of 2016 to 2021. This market ... from USD 117.3 Million in 2016, at a CAGR ...
Breaking Medicine Technology:
(Date:5/31/2016)... , ... May 31, 2016 , ... ... 4, 2016 Cool Vendors in Security Infrastructure Protection report by Gartner1 Inc. , ... a series of research reports evaluating these innovative vendors and their products and ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... ... multichannel marketing services firm and statement solutions provider, for the tenth consecutive ... the May 2016 issue of Advertising Age, and SourceLink ranked eighteenth in the ...
(Date:5/31/2016)... N.J. (PRWEB) , ... May 31, 2016 , ... ... and print media enterprise focused on patients with cancer, has added Cancer ... readers and website visitors with more timely content on continuing successful careers while ...
(Date:5/30/2016)... ... May 30, 2016 , ... As the CDC relaxes ... children and their efforts to keep their households lice free. , According to ... enacting new policies that keep kids in the classroom despite the fact that they ...
(Date:5/30/2016)... ... May 30, 2016 , ... Zane Benefits, ... publication of an original infographic, " Health Benefits Reimbursement Compliance Timeline ." ... Zane Benefits complies with various federal regulations and reforms. , Navigating the new ...
Breaking Medicine News(10 mins):